Articles

Non-adherence to diabetes medication is more likely to occur among young adults, women, those who use retail pharmacies and those who are new to diabetes therapies….

Glucose control has been improving but serious hypoglycemia and insulin mistakes resulting in emergency care are not improving….

An investigational agent for type 2 diabetes may also work as add-on therapy in type 1 disease….

The first wearable artificial pancreas platform based on a smart phone passes early feasibility tests….

A small study warns that weight-loss surgery might accelerate progression of diabetic retinopathy….

The evidence for counting carbs is not substantial….

Serum osteoprotegerin is an independent predictor of cardiovascular complications…

Five years after the release of the ACCORD and ADVANCE studies, some physicians are still searching for answers….

Durability of Dapagliflozin vs. Glipizide as Add-On Therapies in T2DM Inadequately Controlled on Metformin: 4-Year Data   The efficacy, tolerability and safety of dapagliflozin was studied compared to glipizide over a period of 4 years. Dapagliflozin is a novel medication that is a highly selective inhibitor of SLGLT2 and reduces …

Boehringer Ingelheim Pharmaceuticals, Inc., and Eli Lilly and Company are working together to pave a new pathway for type 2 diabetes patients with the sodium glucose co-transporter 2 (SGLT2) inhibitor, empagliflozin. The investigational agent is currently in Phase III clinical trials focusing on four pivotal trials that have concluded with …